Since inhibiting GPC1 activity using an anti-GPC1 monoclonal antibody has shown potential anti-tumor effects in a GPC1-positive ESCC xenograft model, it is expected that GPC1 targeted therapies can be developed for other GPC1-positive solid tumors [18]. This evidence concerns the gene GPC1 and esophageal squamous cell carcinoma.